Combination therapy with iron chelation and ...

4 downloads 0 Views 542KB Size Report
Division of Infectious Diseases, Los Angeles Biomedical Research. Institute, Harbor—University of California Los Angeles (UCLA). Medical Center, 1124 West ...
Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia G. Luo, B. Spellberg, T. Gebremariam, H. Lee, Y. Q. Xiong, S. W. French, A. Bayer & A. S. Ibrahim European Journal of Clinical Microbiology & Infectious Diseases ISSN 0934-9723 Eur J Clin Microbiol Infect Dis DOI 10.1007/s10096-013-2023-5

1 23

Your article is protected by copyright and all rights are held exclusively by SpringerVerlag Berlin Heidelberg. This e-offprint is for personal use only and shall not be selfarchived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”.

1 23

Author's personal copy Eur J Clin Microbiol Infect Dis DOI 10.1007/s10096-013-2023-5

ARTICLE

Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia G. Luo & B. Spellberg & T. Gebremariam & H. Lee & Y. Q. Xiong & S. W. French & A. Bayer & A. S. Ibrahim

Received: 17 September 2013 / Accepted: 15 November 2013 # Springer-Verlag Berlin Heidelberg 2013

Abstract Iron acquisition is a virulence factor for Staphylococcus aureus. We assessed the efficacy of the iron chelator, deferasirox (Def), alone or in combination with vancomycin (Van) against two methicillin-resistant S. aureus (MRSA) strains in vitro and in a murine bacteremia model. In vitro time–kill assays were carried out against MRSA or vancomycin-intermediate S. aureus (VISA) strains. The impact of Def on Van binding to the surface of S. aureus was measured by flow cytometry. Furthermore, we compared the efficacy of Def, Van, or both drugs in treating S. aureus bacteremia in a murine model. Combination therapy reduced MRSA and VISA viability in vitro versus either drug alone or untreated controls (p